CompletedPhase 3

Rivastigmine Capsules in Patients With Probable Vascular Dementia

An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Lead sponsor

Novartis

Asset

Rivastigmine

Listed sites

Recruiting sites

Enrollment

521

actual

Study population

Vascular cognitive impairment / dementia

Key I/E criterion

•Age 50-85

Primary endpoint

•Safety and tolerability of rivastigmine for up

Identifiers

Registered as

Org study IDCENA713BIA05E1

NCT IDNCT00130338

Timeline

Milestones

Study start2002-02 (month precision)

Study first posted2005-08-15estimated

Primary completion2006-05actual (month precision)

Study completion2006-05actual (month precision)

Last update posted2017-03-28actual

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Vascular cognitive impairment / dementia

Eligibility

Who can enroll

Minimum age50 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate

Exclusion criteria

•Retrieved drop-out patients, who have been treated with other cholinergic drugs during the past 4 weeks

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Function / daily living

Safety / tolerability / PK

Function / daily living

1 endpoint

Secondary/protocol endpoint

52 week's treatment with rivastigmine on cognition, activities of daily living, behavior and clinical staging in patients with VaD and probable VaD

descriptive

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Safety and tolerability of rivastigmine for up to 52 weeks of treatment in patients with VaD and probable VaD

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.